Developing nanoparticles that work as "magic bullets" — selectively targeting tumors while sparing normal, healthy tissues
The ability to use nanoparticles to deliver payloads of cancer-fighting drugs to tumors in the body could herald a fundamental change in chemotherapy treatment. But scientists are still at a relatively early stage in the implementation of this technology.
Although developing nanoparticles that work as "magic bullets" — selectively targeting tumors while sparing normal, healthy tissues — is still the goal, the reality is that most of these nanocarriers are removed through the liver and spleen before ever reaching their intended target. And many of the encapsulated drugs can be lost while the carriers circulate in the blood or degraded on the way to tumors.
In a study recently published in the journal ACS Nano, UCLA scientists report that by using engineered mesoporous silica nanoparticles (MSNPs) as delivery vehicles, they were able to achieve significant increases in the percentage of drug-carrying nanoparticles that reach and are retained at tumor sites.
The MSNP platform allows for the introduction of multiple and customized design features that can help optimize the delivery of chemotherapeutic drugs to a variety of cancer types, said the researchers, led by Dr. Andre Nel, a professor of medicine, pediatrics and public health and chief of the nanomedicine division in the UCLA Department of Medicine, and Jeffrey Zink, a professor in the UCLA Department of Chemistry and Biochemistry. Nel and Zink are also members of the California NanoSystems Institute at UCLA.
The team demonstrated a significant increase in particle retention at the tumor site: Approximately 10 to 12 percent of all the drug-loaded particles injected intravenously reached the tumor site. This high tumor distribution is exceptionally good, compared with other polymer- and copolymer-based nanodelivery platforms for which the best passive tumor targeting is in the range of 3.5 to 10 percent of injected particles, the researchers said.
The study also demonstrated efficient drug delivery and tumor cell–killing using the redesigned and optimized MSNP system in mice.
"The amount of doxorubicin being delivered to the tumor site was considerably higher than what could be achieved by the free drug, in addition to allowing efficient delivery into the cancer cells at the tumor site," said Nel, who is also a member of UCLA's Jonsson Comprehensive Cancer Center.
Moreover, the improved drug delivery was accompanied by a significant reduction in systemic side effects such as weight loss and reduced liver and renal injury.
"This is an important demonstration of how the optimal design of the MSNP platform can achieve better drug delivery in vivo," Nel said. "This delivery platform allows effective and protective packaging of hydrophobic and charged anticancer drugs for controlled and on-demand delivery. Not only are these design features superior to induce tumor shrinkage and apoptosis compared to the free drug, but they also dramatically improve the safety profile of systemic doxorubicin delivery."
The UCLA research team also included Dr. Huan Meng and Dr. Tian Xia of the division of nanomedicine; Xue Min and Derrick Y. Tarm of the department of chemistry; and Dr. Zhaoxia Ji of the Center for Environmental Implications of Nanotechnology.
This study was funded by a U.S. Health Service grant from the National Cancer Institute.
The California NanoSystems Institute at UCLA is an integrated research facility located at UCLA and UC Santa Barbara. Its mission is to foster interdisciplinary collaborations in nanoscience and nanotechnology; to train a new generation of scientists, educators and technology leaders; to generate partnerships with industry; and to contribute to the economic development and the social well-being of California, the United States and the world. The CNSI was established in 2000 with $100 million from the state of California. An additional $850 million of support has come from federal research grants and industry funding. CNSI members are drawn from UCLA's College of Letters and Science, the David Geffen School of Medicine, the School of Dentistry, the School of Public Health and the Henry Samueli School of Engineering and Applied Science. They are engaged in measuring, modifying and manipulating atoms and molecules — the building blocks of our world. Their work is carried out in an integrated laboratory environment. This dynamic research setting has enhanced understanding of phenomena at the nanoscale and promises to produce important discoveries in health, energy, the environment and information technology.
UCLA's Jonsson Comprehensive Cancer Center has more than 240 researchers and clinicians engaged in disease research, prevention, detection, control, treatment and education. One of the nation's largest comprehensive cancer centers, the Jonsson Center is dedicated to promoting research and translating basic science into leading-edge clinical studies. In July 2010, the center was named among the top 10 cancer centers nationwide by U.S. News & World Report, a ranking it has held for 10 of the last 11 years.
Media Contacts Jennifer Marcus, 310-267-4839 email@example.com